Navigation Links
Onyx Pharmaceuticals Reports Third Quarter 2009 Financial Results; Nexavar Global Net Sales Top $229 Million, 27% Increase Over Third Quarter 2008
Date:11/3/2009

cial measures that management uses are not prepared in accordance with, and should not be considered in isolation of, or an as alternative to, measurements required by GAAP.

These non-GAAP financial measures exclude the following items from GAAP net income and diluted EPS:

Employee stock-based compensation: Onyx management excludes the effects of employee stock-based compensation because of varying available valuation methodologies, subjective assumptions and the variety of award types; such exclusion facilitates comparisons of Onyx's operating results to peer companies.

Imputed interest related to the application of ASC Subtopic 470-20: Onyx management excludes the effects of imputed interest related to the Company's convertible senior notes due 2016 because this expense is non-cash; such exclusion facilitates comparisons of Onyx's cash operating results to peer companies.

Milestone payments and acquisition related transaction costs: Onyx management excludes the effects of milestone payments and acquisition related transaction costs as they do not relate to the normal and recurring transactions of our business; such exclusions allow for a better representation of the ongoing economics of the business, facilitates comparison to peer companies and is reflective of how Onyx management internally manages the business.

    (6) Under the "if-converted" method, potential common shares related to
    the Company's convertible senior notes were included in non-GAAP net
    income per share - diluted for the three and nine months ended September
    30, 2009 because their effect is dilutive.



                         ONYX PHARMACEUTICALS, INC.
                          CONDENSED BALANCE SHEETS
                                                       (In thousands)
                                                 Sep. 30,           Dec. 31,
                                        
'/>"/>
SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine news :

1. Cumberland Pharmaceuticals to Present at Lazard Healthcare Conference in New York on November 17, 2009
2. Vanda Pharmaceuticals Reports Third Quarter 2009 Results
3. Amylin Pharmaceuticals and Takeda Enter into Worldwide Agreement to Co-Develop and Commercialize Compounds for Obesity
4. VIA Pharmaceuticals Featured at Cambridge Healthtech Institute Discovery on Target 2009 Conference
5. Vanda Pharmaceuticals to Announce Third Quarter 2009 Financial Results on November 2, 2009
6. Amira Pharmaceuticals to Present at the BIO Investor Forum in San Francisco
7. Positive Data from Arena Pharmaceuticals Pivotal BLOOM Trial Demonstrate that Lorcaserin Significantly Improved Markers of Cardiovascular Risk and Glycemic Parameters and was not Associated with Depression or Suicidal Ideation
8. DUSA Pharmaceuticals Named to Deloittes 2009 Technology Fast 500 List of Fastest Growing Companies in North America
9. Peregrine Pharmaceuticals Announces Implementation of 1:5 Reverse Stock Split to Take Effect October 19, 2009
10. Proteolix, Inc. to be Acquired By Onyx Pharmaceuticals
11. Amira Pharmaceuticals to Present at Montgomery Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2014)... Mesa, Arizona (PRWEB) August 31, 2014 For ... ragweed is likely the culprit. Ragweed is the most common ... percent of Americans. , The most common symptoms of ragweed ... and throat, and sneezing. Ragweed allergy can also lead to ... ragweed allergies should consult an allergist about allergy immunotherapy - ...
(Date:8/31/2014)... (PRWEB) September 01, 2014 In order to ... Co.,LTD has announced its latest designs and launched a big ... quality cars. , All the company’s new cars are ... car solutions for the global customers. As a matter of ... high end items. Those who are in need of cheap ...
(Date:8/31/2014)... 31, 2014 LabDoor.com tests the purity ... supplements. According to their website, “We buy products in ... retail stores and online sites. No manufacturer-supplied samples are ... “Stay Healthy with LabDoor,” a recent study was performed ... in the United States for Vitamin D3 content, ...
(Date:8/31/2014)... In the wake of growing consumer concerns ... to require mandatory labeling of GMOs on food and ... that affect their own health and the health of ... measures to eliminate GMOs from dietary supplements, NutriGold has ... initiative with the objective of advancing the non-GMO ...
(Date:8/31/2014)... St. Louis (PRWEB) August 31, 2014 Twin ... identical twins Aiden and Blake Colp before they were born, but ... Care Institute gave them the chance at life. , Now, ... TTTS and the life-saving fetal surgery option available in St. Louis ... TTTS awareness nights at Market Pub House (6655 Delmar Blvd, ...
Breaking Medicine News(10 mins):Health News:AllergyEasy Announces Success Helping Patients Build Immunity To Autumn Ragweed Pollens With Under-the-tongue Drops 2Health News:AllergyEasy Announces Success Helping Patients Build Immunity To Autumn Ragweed Pollens With Under-the-tongue Drops 3Health News:#1 Rank Awarded to NutriGold’s Vitamin D3 Gold Supplement for the "Best Value" in Vitamin D 2Health News:#1 Rank Awarded to NutriGold’s Vitamin D3 Gold Supplement for the "Best Value" in Vitamin D 3Health News:#1 Rank Awarded to NutriGold’s Vitamin D3 Gold Supplement for the "Best Value" in Vitamin D 4Health News:NutriGold Announces its I.C.E. Initiative to Educate Consumers about GMOs in Dietary Supplements 2Health News:NutriGold Announces its I.C.E. Initiative to Educate Consumers about GMOs in Dietary Supplements 3Health News:After a Rare Diagnosis Threatened Their Boys’ Lives, Parents Build Awareness About TTTS and Fetal Surgery Options at The SSM St. Louis Fetal Care Institute. 2Health News:After a Rare Diagnosis Threatened Their Boys’ Lives, Parents Build Awareness About TTTS and Fetal Surgery Options at The SSM St. Louis Fetal Care Institute. 3
... D,ALENE, Idaho, Feb. 28 NightHawk,Radiology Holdings, Inc. (Nasdaq: ... radiology groups across the United States, today announced,that Ernest ... member of the,company,s Board of Directors for personal reasons. ... The company intends to immediately begin a search,to identify ...
... over Prior Year, NEW YORK, Feb. 28 HMS ... quarter and full,year ended December 31, 2007., Revenue for ... with $33.6 million for the same period a year ago. ... common share for the fourth,quarter of 2007, compared to net ...
... 28 VirtualHealth,Technologies, Inc. (OTC Bulletin Board: VHGI) President, ... that predict by 2017, total health,care spending will double ... of every $5 the nation spends according to a ... of the increased costs in health care,projected to top ...
... children with special health care needs, such as autism, ... the care that is federally recommended and that there ... standardized data at the national and state level has ... easily accessible way. , "Parents of children with special ...
... Medical, Inc.,(Nasdaq: ATSI ), manufacturer and marketer ... Dale, President and CEO of,ATS Medical, and Mike ... Renshaw,"Straight to the Heart" conference at the Boston ... the conference is by invitation only. The,conference will ...
... Leonard, Founder and,Chief Surgeon of Leonard Hair Transplant Associates ... availability of a new genetic test for male,pattern baldness. ... England to,offer this to patients., Dr. Robert Leonard ... by genetic male pattern baldness. This exciting new tool ...
Cached Medicine News:Health News:NightHawk Radiology Holdings, Inc. Announces Board Member Departure 2Health News:HMS Holdings Corp. Announces Q4 and Full Year 2007 Results 2Health News:HMS Holdings Corp. Announces Q4 and Full Year 2007 Results 3Health News:HMS Holdings Corp. Announces Q4 and Full Year 2007 Results 4Health News:HMS Holdings Corp. Announces Q4 and Full Year 2007 Results 5Health News:HMS Holdings Corp. Announces Q4 and Full Year 2007 Results 6Health News:HMS Holdings Corp. Announces Q4 and Full Year 2007 Results 7Health News:HMS Holdings Corp. Announces Q4 and Full Year 2007 Results 8Health News:HMS Holdings Corp. Announces Q4 and Full Year 2007 Results 9Health News:HMS Holdings Corp. Announces Q4 and Full Year 2007 Results 10Health News:As Healthcare Spending is Predicted to Exceed 4 Trillion in Less Than 10 Years, Technology will be Called upon to Stem the Tide 2Health News:New child health data show state-to-state differences in quality of care 2Health News:Dr. Robert Leonard First in New England to Offer Genetic Test for Male Pattern Baldness 2
(Date:8/29/2014)... 29, 2014   Mast Therapeutics, Inc. ... today that Santosh Vetticaden, Chief Medical Officer and ... for personal reasons, in mid-September.  Edwin L. ... Aires Pharmaceuticals, which Mast acquired earlier this year, ... Company,s interim Chief Medical Officer.  Dr. Parsley previously ...
(Date:8/29/2014)... 2014  BC Technical, the nation,s leading non-OEM provider ... a leader in sales, service and installation of GE ... Technical to continue to expand their resources and inventory ... modalities. "We are committed to driving ... , president and CEO of BC Technical. "We set ...
(Date:8/29/2014)... 29, 2014 Research and Markets  has announced ... Insight 2014" report to their offering. ... one of the largest segments of pharmaceuticals industry. The numbers ... the available therapies were unable to meet the market requirements. ... for CNS disorder, especially over the past two decades. The ...
Breaking Medicine Technology:Mast Therapeutics Announces Management Change 2Mast Therapeutics Announces Management Change 3Mast Therapeutics Announces Management Change 4BC Technical Acquires Polaris Medical Imaging 2US CNS Disorders Drug Pipeline Insight 2014 2
... Phase I data from XL880, Phase II data from ... SOUTH SAN FRANCISCO, May 30, 2007 /PRNewswire-FirstCall/ --,Exelixis, Inc. ... investigational compounds XL880 and XL999 will be,presented at the ... is being held June 1 to 5 in Chicago,Illinois. ...
... many as,first-line in secondary stroke prevention , ... presented today at the,16th European Stroke Conference in ... dipyridamole plus ASA,is marketed as Aggrenox® or Asasantin® ... vascular events in patients who had,a TIA or ...
Cached Medicine Technology:Six Abstracts Featuring Exelixis Compounds Accepted At ASCO,Conference 2New Research Confirms the Benefit of Extended-Release Dipyridamole,Plus ASA for Preventing Recurrent Stroke in Low- and High-Risk,Patients 2New Research Confirms the Benefit of Extended-Release Dipyridamole,Plus ASA for Preventing Recurrent Stroke in Low- and High-Risk,Patients 3New Research Confirms the Benefit of Extended-Release Dipyridamole,Plus ASA for Preventing Recurrent Stroke in Low- and High-Risk,Patients 4
One end with needle point and other end with medium taper. Stainless steel. Round knurled handle with polished finish. Overall length: 5.7 inches....
This double ended instrument was designed to lift and manipulate the corneal flap in Lasik procedures. Manufactured in titanium....
... This instrument marks the cornea for centration ... flap management in primary and enhancement cases. The ... used to ensure proper alignment of the flap ... atraumatically retract the flap and to flood it ...
Flat curved 1 mm spatula blade 30 mm long with marks at 5 mm, 6 mm and 7 mm from tip, polished finish and round knurled handle. Most popular size or model....
Medicine Products: